The use of a clinical utility index to compare insomnia compounds: a quantitative basis for benefit-risk assessment.

Ouellet, D; Werth, J; Parekh, N; Feltner, D; McCarthy, B; Lalonde, R L

Ouellet, D; Werth, J; Parekh, N; Feltner, D; McCarthy, B; Lalonde, R L.

Affiliation

Ouellet D; Pfizer Global Research and Development, Ann Arbor, Michigan, New London, Connecticut, USA. daniele.x.ouellet@gsk.com

Clin Pharmacol Ther ; 85(3): 277-82, 2009 Mar.

Article in En | MEDLINE | ID: mdl-19078947

Subject(s)

Hypnotics and Sedatives/therapeutic use; Sleep Initiation and Maintenance Disorders/drug therapy; Calcium Channels/metabolism; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hypnotics and Sedatives/adverse effects; Hypnotics and Sedatives/pharmacokinetics; Ligands; Polysomnography/methods; Risk Assessment; Sleep Initiation and Maintenance Disorders/metabolism; Sleep Stages/drug effects; Sleep Stages/physiology; Wakefulness/drug effects; Wakefulness/physiology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hypnotics and Sedatives / Sleep Initiation and Maintenance Disorders Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Clin Pharmacol Ther Year: 2009 Document type: Article Affiliation country: United States Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google